A Rare Collision Medullary and Papillary Thyroid Carcinoma in Autoimmune Thyroid Disease: Case Report [0.03%]
自身免疫性甲状腺疾病中罕见髓样和乳头状甲状腺癌碰撞瘤病例报告
Tena Šimunjak,Bernardica Jurić,Andro Košec et al.
Tena Šimunjak et al.
Background: Collision medullary and papillary thyroid carcinoma (MTC/PTC) is a rare entity, constituting less than 1% of all thyroid malignancies. The concurrent presence of these malignancies in patients with autoimmune ...
Case Reports
Oncology research. 2026 Feb 24;34(3):30. DOI:10.32604/or.2025.072100 2026
CENPF Promotes Gastric Cancer Proliferation through c-Myc-Mediated GLS1 Upregulation and Glutamine Metabolism [0.03%]
CENPF通过c-Myc介导的GLS1上调和谷氨酰胺代谢促进胃癌增殖
Min Dong,Zongchang Song,Xiaohui Lu et al.
Min Dong et al.
Background: Gastric cancer (GC) remains highly lethal, with metabolic reprogramming as a key hallmark. This study explores Centromere Protein F (CENPF)'s role in GC pathogenesis, specifically its regulation of glutamine m...
Retraction: Long Noncoding RNA PVT1 Promotes Melanoma Progression via Endogenous Sponging miR-26b [0.03%]
撤稿：长链非编码RNA PVT1通过内源吸附miR-26b促进黑色素瘤进展
Oncology Research Editorial Office
Oncology Research Editorial Office
[This retracts the article DOI: 10.3727/096504017X14920318811730.]. © 2026 The Author. Published by Tech Science Press.
Advances in Systemic Therapy for Unresectable Hepatocellular Carcinoma: Commentary on The Impact of the STRIDE Regimen in HIMALAYA Trial [0.03%]
不可切除肝细胞癌系统治疗进展：HIMALAYA试验STRIDE方案影响述评
Leenah Abdulgader,Abdullah Esmail
Leenah Abdulgader
Unresectable hepatocellular carcinoma (HCC) remains a global challenge, with limited effective treatment options for advanced-stage disease. The HIMALAYA trial (phase III randomized study that evaluated the STRIDE regimen) introduced the Si...
Mechanisms and Therapeutic Strategies for HCV/HBV-Associated B-Cell Non-Hodgkin's Lymphomas: A Viewpoint [0.03%]
丙型肝炎/乙型肝炎病毒相关B细胞非霍奇金淋巴瘤的作用机制及治疗策略：观点类文章
Guido Carloni,Monica Rinaldi
Guido Carloni
Hepatitis C virus (HCV) and hepatitis B virus (HBV) infections are increasingly recognized as significant etiological factors in the pathogenesis of B-cell non-Hodgkin's lymphomas (B-NHLs). Epidemiological and molecular studies have demonst...
Marcia Eduarda Viana Luna,Gustavo Jacob Lourenço,Juliana Carron
Marcia Eduarda Viana Luna
This literature review explores the complex interaction between p53 and microRNAs (miRNAs) in the occurrence and progression of breast cancer (BC), the most common and lethal tumor type among women. BC is a multifactorial disease resulting ...
Epigenomic and Metabolic Interplay in the Development of Metastatic Brain Tumors [0.03%]
表观遗传组和代谢在转移性脑肿瘤发生中的相互作用
Vishal Rastogi,Deepak Verma,Saurabh Verma et al.
Vishal Rastogi et al.
Metastatic brain tumors undergo profound metabolic-epigenetic reprogramming driven by the unique constraints of the brain microenvironment. Hypoxia-inducible factor-1α (HIF1α) enhances glycolytic flux, lactate accumulation, and histone la...
Therapeutic Potential of Fingolimod and Dimethyl Fumarate in Preclinical Pancreatic Cancer Models [0.03%]
Fingolimod和Dimethyl Fumarate在胰腺癌的临床前模型中的治疗潜力
Pauline Gousseau,Laurie Genest,Guillaume Froget et al.
Pauline Gousseau et al.
Objectives: The five-year survival rate for pancreatic cancer is notably low, posing a significant challenge to patient health. The primary treatments are radiotherapy and chemotherapy, sometimes combined with targeted th...
Ugonin J Inhibits EMT and Migration in Prostate Cancer by Suppressing ADAM9 Expression [0.03%]
乌头类双苄基异喹啉生物碱ugonin J通过抑制ADAM9表达抑制前列腺癌的EMT和迁移作用
Jo-Yu Lin,Tien-Huang Lin,Ya-Jing Jiang et al.
Jo-Yu Lin et al.
Background: Prostate cancer (PCa) is the most prevalent malignancy in men and often correlates with distant metastasis in its advanced stages. The study aimed to investigate the effects of Ugonin J, a natural compound iso...
Next Generation DNA Damage Response Inhibitors: Harnessing Nanocarriers and Tumor Microenvironment for Precision Cancer Therapy [0.03%]
下一代DNA损伤响应抑制剂：利用纳米载体和肿瘤微环境实现精准癌症治疗
Abhishikt David Solomon,Himanshu Kumar Vats,Shivam Chowdhary et al.
Abhishikt David Solomon et al.
Tumor survival, genomic stability, and therapy resistance are dictated by the DNA damage response (DDR). Although poly (ADP-ribose) polymerase (PARP) inhibitors have established the DDR as a therapeutic target, many tumors evade first-gener...